Analyst firms · Raymond James · DOCS

Raymond James DOCS price target and rating history

Doximity Inc. (DOCS) · Technology

Raymond James rates Doximity Inc. (DOCS) Strong Buy with a $65 price target, as of its latest action on Nov 21, 2025. It has published 5 rating actions on DOCS since July 2021, including 1 upgrade and 0 downgrades. Across 12 firms with a DOCS price target in the last 12 months, the median target is $27. Raymond James's $65 is 141% above that.

Current rating

Strong Buy

Price target

$65

Median target, all firms

$27

Actions on DOCS

5

Raymond James price target on DOCS

Every Raymond James rating on DOCS

• Nov 21, 2025
  UpgradeRaymond James upgrades to Strong Buy from Outperform, price target $65
• Feb 9, 2022
  ReiterateRaymond James cuts its price target to $60 from $80, keeps Outperform
• Nov 10, 2021
  ReiterateRaymond James raises its price target to $80 from $62, keeps Outperform
• Aug 11, 2021
  ReiterateRaymond James raises its price target to $62 from $60, keeps Outperform
• Jul 19, 2021
  InitiateRaymond James starts coverage at Outperform, price target $60

How other firms rate DOCS

Each firm's latest rating and stated target in the last 12 months.

Questions about Raymond James and DOCS

What is Raymond James's price target for DOCS?

Raymond James's latest stated price target for Doximity Inc. (DOCS) is $65, from its action on Nov 21, 2025.

What is Raymond James's rating on DOCS?

Raymond James rates DOCS Strong Buy, a bullish rating, as of Nov 21, 2025.

When did Raymond James last change its view on DOCS?

On Nov 21, 2025, Raymond James upgrades to Strong Buy from Outperform, price target $65.

How does Raymond James's DOCS target compare with other analysts?

Across 12 firms with a DOCS price target in the last 12 months, the median target is $27. Raymond James's $65 is 141% above that.

More DOCS rating histories

• Wells Fargo7
• BofA Securities6
• Barclays4
• KeyBanc Capital Markets3
• Robert W. Baird3
• BTIG3
• Jefferies3
• Truist Securities3
• Evercore ISI3
• Canaccord Genuity4
• Morgan Stanley8
• Goldman Sachs6
• Piper Sandler4
• Leerink Partners4
• Needham6
• J.P. Morgan4
• Guggenheim3

All Raymond James ratingsDOCS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.